Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Drug Metabolism and Drug Interactions

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1515/dmdi-2013-0032PMID 24088607
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

  2013cited by this paper
• Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function

  2013cited by this paper
• Potential role of CYP2D6 in the central nervous system

  2013cited by this paper
• Is maternal opioid use hazardous to breast-fed infants?

  2012cited by this paper
• Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects

  2012cited by this paper
• Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

  2012cited by this paper
• Fruit Juices as Perpetrators of Drug Interactions: The Role of Organic Anion–Transporting Polypeptides

  2012cited by this paper
• CYP2D6 and the severity of suicide attempts.

  2012cited by this paper
• Clinical Response and Side Effects of Metoclopramide: Associations With Clinical, Demographic, and Pharmacogenetic Parameters

  2012cited by this paper
• Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.

  2012cited by this paper
• Just how feasible is pharmacogenetic testing in the primary healthcare setting?

  2012cited by this paper
• The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients.

  2012cited by this paper
• Impact of Obesity on Drug Metabolism and Elimination in Adults and Children

  2012cited by this paper
• Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance

  2011cited by this paper
• CYP2D6 in the brain: genotype effects on resting brain perfusion

  2011cited by this paper
• Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.

  2011cited by this paper
• CYP2D6 polymorphism in patients with eating disorders

  2010cited by this paper
• Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations

  2009cited by this paper
• Postmenstrual Age and CYP2D6 Polymorphisms Determine Tramadol O-demethylation in Critically Ill Neonates and Infants

  2008cited by this paper
• Ontogeny of Dextromethorphan O‐ and N‐demethylation in the First Year of Life

  2007cited by this paper
• Pharmacokinetics of Mirtazapine: Enantioselective Effects of the CYP2D6 Ultra Rapid Metabolizer Genotype and Correlation with Adverse Effects

  2007cited by this paper
• Comparative cytochrome P450 ‐1A1, ‐2A6, ‐2B6, ‐2C, ‐2D6, ‐2E1, ‐3A5 and ‐4B1 expressions in human larynx tissue analysed at mRNA level

  2006cited by this paper
• The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment

  2006cited by this paper
• Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.

  2003cited by this paper
• CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

  2002cited by this paper
• Parkinson’s disease, CYP2D6 polymorphism, and age

  2001cited by this paper
• Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain.

  2001cited by this paper
• Comparison of CYP2D6 Content and Metoprolol Oxidation Between Microsomes Isolated from Human Livers and Small Intestines

  1999cited by this paper
• In vivo age‐related changes in hepatic drug‐oxidizing capacity in humans

  1998cited by this paper
• Tryptamine: a possible endogenous substrate for CYP2D6.

  1997cited by this paper
• Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.

  1995cited by this paper
• CYP2D6-related oxidation polymorphism in Italy.

  1994cited by this paper
• Genetic basis for differences in debrisoquin polymorphism between a spanish and other white populations

  1994cited by this paper
• Polymorphic hydroxylation of Debrisoquine in man.

  1977cited by this paper

• Investigation of CYP2D6 (*2,*3,*4,*7,*10,*41) gene polymophisms in pediatric cardiology patients

  2025cites this paper
• Impact of genetic variations of gene involved in regulation of metabolism, inflammation and coagulation on pathogenesis of cardiac injuries associated with COVID-19.

  2024cites this paper
• The respiratory depressant effects of mitragynine are limited by its conversion to 7‐OH mitragynine

  2022cites this paper
• Commonly used surfactants sodium dodecyl sulphate, cetylpyridinium chloride and sodium laureth sulphate and their effects on antioxidant defence system and oxidative stress indices in Cyprinus carpio L.: an integrated in silico and in vivo approach

  2022cites this paper
• The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis

  2020cites this paper
• Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm

  2020cites this paper
• Co-Evolution between New Coronavirus (SARS-CoV-2) and Genetic Diversity: Insights on Population Susceptibility and Potential Therapeutic Innovations

  2020cites this paper
• Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant?

  2018cites this paper
• The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo

  2018cites this paper
• Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans

  2018cites this paper
• Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review

  2018cites this paper
• Pharmacogenetics and Psychiatric Care: A Review and Commentary

  2018cites this paper
• Pharmacokinetic interactions of curcuminoids with conventional drugs: A review.

  2017cites this paper
• Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

  2017cites this paper
• Pharmacodynamic Genes Gene Tested : Serotonin Transporter ( SLC

  2017cites this paper
• Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors

  2015cites this paper
• Pharmacogenetics Informed Decision Making in Adolescent Psychiatric Treatment: A Clinical Case Report

  2015cites this paper